Clinical Trial Update: Lomustine and Intermediate Dose Cytarabine in Older Patients With AML [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating lomustine plus intermediate-dose cytarabine in older adults with Acute Myeloid Leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Lomustine (Lomustine)

Snippet

Sponsor: French Innovative Leukemia Organisation | Conditions: Acute Myeloid Leukemia | Phase 3 | Status: COMPLETED